Mylan NV rejected Teva Pharmaceutical Industries Ltd's unsolicited $40 billion takeover offer, saying it 'grossly undervalues' the company. The offer, announced last week, will expose Mylan to a 'problematic culture and leadership with poor record of delivering shareholder value,' Mylan said on Monday.
